EXOZYMES INC.
EXOZ evidence brief
What we can confirm
- BioSniper Score:
- 9.1 / 10
- Market Cap:
- $58.5M
What it means
What to watch
Prepared research question
What matters most for EXOZ—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · EXOZ
eXoZymes Inc. (EXOZ) is a pre-revenue, development-stage biotechnology company that uses an AI-enhanced, cell-free enzyme platform to produce nutraceuticals and novel medicines from renewable feedstocks.
Key risk: Cash runway
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$58.5M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
eXoZymes Inc. (EXOZ) is a pre-revenue, development-stage biotechnology company that uses an AI-enhanced, cell-free enzyme platform to produce nutraceuticals and novel medicines from renewable feedstocks.
- eXoZymes is a pre-revenue, development-stage biotechnology company [sec_mda · as of 2026-08-13].
- Cash and equivalents were $5.7M as of 2026-06-30, with a net loss of -$2.9M and shareholders' equity of $3.7M [sec].
- The company reported a tenfold increase in NCT process productivity versus its March pilot campaign [news · published 2026-08-20].
- eXoZymes has secured non-dilutive grants including a $3 million share of a $9.2 million NSF grant and a $283,805 NIH BioClick grant [sec_mda · as of 2026-08-13].
- Management expects to select a manufacturing partner by the end of Q3 2026 and identify a market launch partner [news · published 2026-08-20].
What works
- The company's cell-free, multi-step enzyme platform is differentiated and aims to be more environmentally friendly than traditional methods [sec_mda · as of 2026-08-13].
- eXoZymes has secured significant non-dilutive grant funding, including a $3M share of a $9.2M NSF grant and a $283,805 NIH grant [sec_mda · as of 2026-08-13].
- The NCT program achieved a tenfold increase in process productivity compared to its prior pilot campaign, indicating technical progress [news · published 2026-08-20].
What to weigh
- The company is pre-revenue and has a tight cash runway; as of March 31, 2026, working capital was approximately $507,586 and not sufficient to fund operations for a full twelve-month period [sec_mda · as of 2026-05-14].
- eXoZymes reported a net loss of -$2.9M for the period ending 2026-06-30 [sec].
- The company does not have any committed sources of additional financing beyond grants and the recent offering [sec_mda · as of 2026-05-14].
From the filings
Quoted directly from source documents.
eXoZymes is a pre-revenue, development-stage company
“eXoZymes is a biotechnology, pre-revenue, development stage company.”
SEC MD&A · August 13, 2026
NCT process productivity increased tenfold
“a reported tenfold increase in process productivity versus its March pilot campaign”
News · August 20, 2026
Working capital insufficient for 12 months as of March 31, 2026
“the Company's existing working capital is not sufficient to fund operations for a full twelve-month period, determined as of March 31, 2026”
SEC MD&A · May 14, 2026
Company received $3M share of $9.2M NSF grant
“the Company was awarded a key industrial partnership, with a $3 million share of a $9.2 million grant.”
SEC MD&A · August 13, 2026
Risks & what to watch (3)›
Key risks
- Cash runway — Working capital of ~$507,586 as of March 31, 2026, insufficient for 12 months of operations [sec_mda · as of 2026-05-14].
- Pre-revenue status — Company is pre-revenue with net loss of -$2.9M as of 2026-06-30 [sec].
- No committed financing — No committed sources of additional financing beyond grants and recent offering [sec_mda · as of 2026-05-14].
What to watch
- Selection of a manufacturing partner by end of Q3 2026 [news · published 2026-08-20].
- Identification of a market launch partner for the NCT program [news · published 2026-08-20].
- Ability to secure additional non-dilutive grants or financing to extend cash runway [sec_mda · as of 2026-08-13].
- Progress toward commercializing NCT and achieving first revenue [news · published 2026-08-22].
Sources: News · SEC MD&A · Generated October 4, 2026 · How we verify sources →
Run EXOZYMES INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available EXOZYMES INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 1.18 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
5 buys · 0 sells (180d)
Financials
Short Interest
as of Apr 20, 2026- % of float
- 0.3%
- Days to cover
- 2.8
- Shares short
- 10,666
- Daily short volume (Jun 8, 2026)
- 35.5%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
EXOZ short interestGovernance
Frequently asked questions
What is the AI investment thesis for EXOZYMES INC.?
eXoZymes Inc. (EXOZ) is a pre-revenue, development-stage biotechnology company that uses an AI-enhanced, cell-free enzyme platform to produce nutraceuticals and novel medicines from renewable feedstocks.
Who is the CEO of EXOZYMES INC.?
Mr. Michael Heltzen is the chief executive officer of EXOZYMES INC. (EXOZ).
Where is EXOZYMES INC. headquartered?
EXOZYMES INC. (EXOZ) is headquartered in Monrovia, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.